文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

头盔压力支持、持续气道正压与经鼻高流量氧疗在低氧性呼吸衰竭中的各自效应:随机交叉临床试验

Respective Effects of Helmet Pressure Support, Continuous Positive Airway Pressure, and Nasal High-Flow in Hypoxemic Respiratory Failure: A Randomized Crossover Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2023-01-01
一句话结论在PaO2/FiO2≤200的低氧患者中,头盔NIV较HFNO降低吸气努力,CPAP与NIV均改善氧合和肺容积,但ΔPL无显著差异。

研究纳入15例低氧性呼吸衰竭患者(PaO2/FiO2≤200),随机交叉接受1小时HFNO(60 L/min)、头盔NIV(PEEP=14 cm H2O,压力支持=12 cm H2O)和CPAP(PEEP=14 cm H2O)。主要发现:NIV的ΔPES低于CPAP和HFNO;ΔPL在各治疗间无统计学差异;NIV和CPAP的PaO2/FiO2显著高于HFNO;NIV和CPAP均增加潮气量和呼气末肺容积,主要因背侧肺区通气增加;HFNO期间14/15例存在>10% Vt的摆尾效应,CPAP可减轻,NIV进一步减轻。结论提示头盔NIV可降低吸气努力,CPAP与NIV均可改善氧合和肺容积。

要点

  • 在PaO2/FiO2≤200的低氧患者中,头盔NIV(PEEP=14 cm H2O,压力支持=12 cm H2O)的ΔPES中位数为5(3-9)cm H2O,低于CPAP的13(10-19)cm H2O和HFNO的10(8-13)cm H2O。
  • 头盔NIV和CPAP的PaO2/FiO2分别为166(136-215)和175(158-281),均显著高于HFNO的120(107-149)。
  • 与HFNO相比,NIV和CPAP分别使潮气量平均增加70%(95%CI 17-122%)和93%(95%CI 30-155%),使呼气末肺容积平均增加198%(95%CI 67-330%)和263%(95%CI 121-407%)。
  • HFNO期间14/15例患者存在涉及>10% Vt的摆尾效应,CPAP可减轻,NIV进一步减轻。
  • ΔPL在各治疗间无统计学差异,提示三种支持方式对肺扩张的影响无显著差别。

适用人群与场景

  • 低氧性呼吸衰竭患者,PaO2/FiO2≤200,共15例。

诊断标准与关键阈值

  • 纳入标准:低氧血症,PaO2/FiO2≤200。

处置流程与药物剂量

  • HFNO:流量60 L/min,FiO2恒定,持续1小时。
  • 头盔NIV:PEEP=14 cm H2O,压力支持=12 cm H2O,FiO2恒定,持续1小时。
  • 头盔CPAP:PEEP=14 cm H2O,FiO2恒定,持续1小时。
  • 三种治疗按随机顺序进行,每种1小时。

研究设计与关键结果

  • 随机交叉临床试验,15例低氧性呼吸衰竭患者(PaO2/FiO2≤200),比较1小时HFNO(60 L/min)、头盔NIV(PEEP=14 cm H2O,压力支持=12 cm H2O)和CPAP(PEEP=14 cm H2O)的效应。
  • 主要指标ΔPES:NIV中位数5(3-9)cm H2O vs CPAP 13(10-19)cm H2O vs HFNO 10(8-13)cm H2O;NIV vs CPAP P=0.001,NIV vs HFNO P=0.01。
  • ΔPL在各治疗间无统计学差异。
  • PaO2/FiO2:NIV 166(136-215) vs HFNO 120(107-149),P=0.002;CPAP 175(158-281) vs HFNO 120(107-149),P=0.001。
  • 潮气量平均变化:NIV较HFNO增加70%(95%CI 17-122%),P=0.02;CPAP较HFNO增加93%(95%CI 30-155%),P=0.002。
  • 呼气末肺容积平均变化:NIV较HFNO增加198%(95%CI 67-330%),P=0.001;CPAP较HFNO增加263%(95%CI 121-407%),P=0.001;主要因背侧肺区通气/通气增加。
  • HFNO期间14/15例患者存在涉及>10% Vt的摆尾效应,CPAP可减轻,NIV进一步减轻。

证据类型、等级与局限

  • 证据类型:随机交叉临床试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在PaO2/FiO2≤200的低氧患者中,头盔NIV(PEEP=14 cm H2O,压力支持=12 cm H2O)可降低吸气努力(ΔPES),CPAP无此效应。
  • 头盔NIV和CPAP均可改善氧合、增加潮气量和呼气末肺容积,效应相似,且均不改变ΔPL。
  • 头盔NIV较CPAP进一步减轻摆尾效应,CPAP亦可减轻HFNO期间的摆尾效应。

指南或共识出处

  • 临床试验注册号:NCT04241861。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: The respective effects of positive end-expiratory pressure (PEEP) and pressure support delivered through the helmet interface in patients with hypoxemia need to be better understood. Objectives: To assess the respective effects of helmet pressure support (noninvasive ventilation [NIV]) and continuous positive airway pressure (CPAP) compared with high-flow nasal oxygen (HFNO) on effort to breathe, lung inflation, and gas exchange in patients with hypoxemia (PaO2/FiO2 ⩽ 200). Methods: Fifteen patients underwent 1-hour phases (constant FiO2) of HFNO (60 L/min), helmet NIV (PEEP = 14 cm H2O, pressure support = 12 cm H2O), and CPAP (PEEP = 14 cm H2O) in randomized sequence. Measurements and Main Results: Inspiratory esophageal (ΔPES) and transpulmonary pressure (ΔPL) swings were used as surrogates for inspiratory effort and lung distension, respectively. Tidal Volume (Vt) and end-expiratory lung volume were assessed with electrical impedance tomography. ΔPES was lower during NIV versus CPAP and HFNO (median [interquartile range], 5 [3-9] cm H2O vs. 13 [10-19] cm H2O vs. 10 [8-13] cm H2O; P = 0.001 and P = 0.01). ΔPL was not statistically different between treatments. PaO2/FiO2 ratio was significantly higher during NIV and CPAP versus HFNO (166 [136-215] and 175 [158-281] vs. 120 [107-149]; P = 0.002 and P = 0.001). NIV and CPAP similarly increased Vt versus HFNO (mean change, 70% [95% confidence interval (CI), 17-122%], P = 0.02; 93% [95% CI, 30-155%], P = 0.002) and end-expiratory lung volume (mean change, 198% [95% CI, 67-330%], P = 0.001; 263% [95% CI, 121-407%], P = 0.001), mostly due to increased aeration/ventilation in dorsal lung regions. During HFNO, 14 of 15 patients had pendelluft involving >10% of Vt; pendelluft was mitigated by CPAP and further by NIV. Conclusions: Compared with HFNO, helmet NIV, but not CPAP, reduced ΔPES. CPAP and NIV similarly increased oxygenation, end-expiratory lung volume, and Vt, without affecting ΔPL. NIV, and to a lesser extent CPAP, mitigated pendelluft. Clinical trial registered with clinicaltrials.gov (NCT04241861).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Menga LS, Delle Cese L, Rosà T, et al. Respective Effects of Helmet Pressure Support, Continuous Positive Airway Pressure, and Nasal High-Flow in Hypoxemic Respiratory Failure: A Randomized Crossover Clinical Trial. Am J Respir Crit Care Med. 2023. PMID: 36378814. doi:10.1164/rccm.202204-0629OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。